Furthering its goal to grow the reach of its mRNA vaccines and guard against future pandemics, Moderna cleared a key ...

Shares of several vaccine makers soared after reports suggest that the Biden administration is in discussions with Moderna MRNA and Pfizer PFE to set up a possible vaccine program aimed at preventing ...

RNA vaccines train the immune system in a similar way to traditional vaccines, but they use a different strategy to get there ...

Concern is growing among public health experts that anti-vaccine sentiments within federal and state governments may derail ...

Shares of some U.S. biotechnology companies including Moderna (MRNA) plunged on Monday after reports that the top vaccine official at the U.S.

US mRNA specialist Moderna (Nasdaq: MRNA) has announced that its manufacturing facility in the UK has been granted a manufacturer’s license by the Medicines and Healthcare products Regulatory Agency ...

"There will not be any research funded by NIH on mRNA vaccines," the scientist in New York similarly told the outlet. "MAGA people are convinced that these vaccines have killed and maimed tens of ...

Vaccine stocks are down after the health agency's top immunization official announced the move Monday, citing Secretary ...

CAMBRIDGE, MA / ACCESS Newswire / March 31, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the Australian Therapeutic Goods ...

From fluoride, vaccines and beef tallow, here's how he might "go wild" on biotech stocks. CAMBRIDGE, MA / ACCESS Newswire / April 10, 2025 / Moderna, Inc. (NASDAQ:MRNA), today announced that it ...

However, in the later stages of the pandemic, demand for the product declined, and Moderna shifted to a loss. For example, last year, the company brought in $3.2 billion in revenue, compared to more ...

Shares of vaccine-maker Moderna MRNA closed at $34.71 on Monday, close to their 52-week low of $29.25. Moderna is facing several headwinds, including the declining COVID-19 vaccine and the soft ...